compared to those in AD conditions. Furthermore, T-DM1 significantly inhibited colony formation in soft agar compared to control IgG or trastuzumab. Since anoikis is a pre-requisite for metastasis, these results suggest that HER2 expression contributes to the establishment of metastasis and T-DM1 could have anti-metastatic potential. The bladder cancer cell line with the highest HER2 expression (BOY) was equivocal HER2 amplification by FISH (HER2/CEP17 ratio: 1.8, HER2 copy number: 4.7), which is known to correspond to HER2 IHC score 2+ in patient tissue. BOY responded most sensitively to T-DM1, and low concentration (10nM) T-DM1 induced apoptosis only in BOY. This suggests T-DM1 could be effective in patients with HER2 overexpression (IHC score 2+/3+).
INTRODUCTION AND OBJECTIVES: Background: Genetic alterations within ERCC2 correlate with extraordinary responses to neoadjuvant cisplatin-based chemotherapy and bladder-sparing ionizing radiation (IR) in muscle-invasive bladder cancer (MIBC) . Two studies correlated ERCC2 mutations with pathologic response to chemotherapy and improved disease-free and bladder intact survival following trimodality therapy. We sought to characterize the biological significance of these mutations in bladder cancer cells using CRISPR/ Cas9-mediated ablation of ERCC2 function.
METHODS: Methods: The ERCC2 T484A/M point mutation was the most common alteration (4 of 36 patients) within a prospectively collected cohort of 299 bladder cancer patients sequenced at our institution. We infected the ERCC2 wild-type KU19-19 bladder cancer cell line with a CRISPR/Cas9 lentivirus targeting residues 481-487 of ERCC2 and identified a cell clone harboring an ERCC2 in-frame deletion (M483_T484del). Following exposure to cisplatin and IR, cell viability was examined using Cell-titer Glo and clonogenic assays. Apoptosis was gauged by subG1 cell fraction measurement by flow cytometry.
RESULTS: Results: ERCC2 mutant cells exhibited significantly increased cisplatin sensitivity compared to parental cells (IC50 0.3uM vs 2.0uM, p<0.0001). Cisplatin treatment after 48 hours resulted in increased apoptosis in ERCC2 mutant vs parental cells (sub-G1 fraction 52% vs 16%, p¼0.01). ERCC2 mutant cells were more sensitive to combined IR (2 Gy) and cisplatin (1uM) INTRODUCTION AND OBJECTIVES: Urothelial carcinoma (UC) of the bladder is susceptible to immunotherapy with checkpoint inhibitors, including anti-programmed cell death ligand-1 (anti-PD-L1). However, checkpoint inhibitor treatment has not yet extended to patients with localized UC. We hypothesize that intravesical TMX-101, a bladder formulation of a toll-like receptor-7 agonist that demonstrates efficacy against carcinoma in situ, will enhance the anti-tumor effects of systemic anti-PD-L1 in an orthotopic mouse model of UC.
METHODS: We used 32 female C57Bl/6 mice aged 6-8 weeks with MB49 murine UC tumors implanted into the bladder. Treatments (intravesical TMX-101 or vehicle and intraperitoneal anti-PD-L1 or isotype) were given on days 3, 6, and 9 following tumor implantation. Mice were treated with one of four regimens: 1) vehicle + isotype, 2) TMX-101 + isotype, 3) Vehicle + anti-PD-L1, or 4) combination therapy (TMX-101 + anti-PD-L1). Mice were euthanized on day 11. Bladder weight was used as a measure of tumor burden and compared using the Kruskal-Wallis test. Fluorescence activated cell sorting (FACS) analysis of blood, spleen, and regional lymph nodes was performed for T-cell populations.
RESULTS: Mean bladder weight in mice treated with TMX-101 (34.8AE4.7mg), anti-PD-L1 (34.8AE3.8mg), and combination TMX-101 and anti-PD-L1 (26.4AE3.5mg) was less than in control treated mice (84.8AE29.1mg). However, only the combination therapy was statistically significant (p<0.05; Figure 1 ). As controls, no differences in kidney or spleen weights were found between groups. Histologic analysis confirmed immune cell infiltration in tumors. FACS analysis of blood, spleen, and lymph nodes showed no differences in relative T-cell populations.
CONCLUSIONS: Intravesical TMX-101 and anti-PD-L1 combination therapy significantly reduced tumor burden as demonstrated by bladder weights and histology in an orthotopic mouse model of nonmuscle invasive bladder UC. 
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INTRODUCTION AND OBJECTIVES: Mycobacterium bovis
bacillus Calmette-Guerin (BCG) has been used for the treatment of bladder cancer for almost 40 years, although the antitumor effector mechanisms remain elusive. Recent our study demonstrated interleukin (IL)-17 produced by gdT cells plays a key role in the recruitment of neutrophlis to the bladder after BCG instillation, which is important for Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1313
